Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva rasagiline submission

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Teva submits rasagiline NDA Aug. 8 for treatment of Parkinson's disease (PD). Rasagiline differs from other MAO-B inhibitors "in its chemical structure, its greater potency, lack of amphetamine metabolites and once-a-day dosing," the firm says. Somerset's Eldepryl (selegiline), the only approved PD drug in the MAO-B class, is administered twice daily. Teva will likely stress efficacy in the "off" period when PD symptoms are not adequately controlled. In the 18-week LARGO trial, rasagiline added to levodopa reduced "off" time by 1.2 hours daily or 21%. Rasagiline also significantly improved motor function based on the Unified PD Rating Scale in "on" and "off" states, while the comparator, Novartis' Comtan (entacapone), similarly improved scores in the "on" state but did not impact scores in the "off" state. Teva recently signed a co-promotion deal with Eisai; the firms are also developing the agent for Alzheimer's disease (1Pharmaceutical Approvals Monthly June 1, 2003, In Brief)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS002373

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel